Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, novembre 17
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Helus Pharma Inc
HELP
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$7.67
-1.20
-13.53%
In chiusura: Nov 13, 4:00 PM EST
$8.02
-0.85
-9.58%
Pre-mercato: 8:16 AM EST
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
PRO
Perché si muove?:
Helus Pharma shares are trading lower after the company reported wider-than...
Utili:
I risultati di Q2 2026 sono stati pubblicati in data lun nov 16th, prima dell'apertura del mercato
Helus Pharma Financials
Helus Pharma (HELP) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Helus Pharma Q2 EPS $(1.41) Misses $(0.64) Estimate
Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(0.64) by 120.31 percent. This is a 1.44 percent decrease over losses of $(1.39) per share from
Benzinga Newsdesk
PRO
Helus Pharma Q2 Net Loss $103.1M vs $33.7M Prior
Benzinga Newsdesk
PRO
Helus Pharma Q1 EPS $(0.91) Beats $(1.07) Estimate
Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.07) by 14.95 percent. This is a 17.27 percent increase over losses of $(1.10) per share from the
Benzinga Newsdesk
PRO
Helus Pharma Q4 EPS $(0.85) Beats $(1.11) Estimate
Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.11) by 23.42 percent. This is a 16.67 percent increase over losses of $(1.02) per share from the
Benzinga Newsdesk
PRO
Helus Pharma Q3 EPS $(1.00) Misses $(0.80) Estimate
Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.80) by 25 percent. This is a 164.55 percent decrease over losses of $(0.38) per share from the
Benzinga Newsdesk